Considering Equity and Consumer Impacts of GLP-1 Drugs – A UBS Economist Weighs In
Health Populi
APRIL 8, 2024
Since the introduction of GLP-1 drugs on the market, their use has split into two categories: for obesity and “recreationally,” according to the Chief Economist with UBS (formerly known as Union Bank of Switzerland). Paul Donovan, said economist, discusses The economics of getting thin in his regularly published comment blog.
Let's personalize your content